Andrew Dauber, MD, MMSc

  • Chief of Endocrinology
  • Children’s National Hospital

Andrew Dauber, M.D., MMSc, is the chief of endocrinology at Children’s National Hospital. As a pediatric endocrinologist, Dr. Dauber works in all areas of pediatric endocrinology, but specializes in studying and treating growth disorders.

Dr. Dauber has published more than 65 studies and regularly speaks at international pediatric endocrinology conferences, discussing a variety of topics, including clinical clues to identify rare genetic growth conditions, genetic factors that influence height and the timing of puberty, as well as novel genetic disorders that he has helped identify. He is the recipient of the 2020 Richard E. Weitzman Outstanding Early Career Investigator Award from the Endocrine Society for successfully applying innovative genetic technologies to pediatric endocrinology.

With a medical degree and a Master’s of Medical Sciences in Clinical Investigation from Harvard Medical School, Dr. Dauber finds it natural to merge academic research with its clinical counterparts to accelerate cutting-edge treatment and multidisciplinary care. He is currently working with pediatric health centers to integrate genomics into patient registries and electronic health records, harnessing large data sets, including whole-exome sequences, to help clinicians identify and treat high-risk patients.

Over the next few years, Dr. Dauber will create an endocrinology research program at Children’s National, transforming the type of care that children with endocrine disorders receive. This will make it easier for parents to find comprehensive resources for rare conditions, thyroid problems, growth disorders, early or delayed puberty, as well as type 1 and type 2 diabetes.

Dr. Dauber also has experience with guiding joint infrastructures and engines of innovation. Previously, he served as the program director and director of translational research at the interdisciplinary Cincinnati Center for Growth Disorders at Cincinnati Children’s Hospital Medical Center. Additionally, he was the director of their Genomics First for Undiagnosed Diseases Program and guided medical residents and fellows as an associate professor of pediatrics at the University of Cincinnati. He held similar roles as the assistant medical director for the clinical research unit at Boston Children’s Hospital and as an assistant professor in pediatrics at Harvard Medical School.

Dr. Dauber holds board certifications in pediatrics and pediatric endocrinology from the American Board of Pediatrics. He is an active member of and has received several awards and honors from the Endocrine Society, Pediatric Endocrine Society, European Society of Pediatric Endocrinology and the Society for Pediatric Research.


  • Vosoritide for Hypochondroplasia and Other Genetic Conditions

    Similar to achondroplasia, hypochondroplasia is also a form of short-limbed dwarfism. Dr. Andrew Dauber is the lead investigator for the study of Vosoritide for Selected Genetic Causes of Short Stature. In his presentation, Dr. Dauber will go in-depth on his study and how it benefits those with hypochondroplasia and other genetic conditions.